Page last updated: 2024-12-08
cgp 6809
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 163402 |
| SCHEMBL ID | 11226054 |
| MeSH ID | M0109655 |
Synonyms (10)
| Synonym |
|---|
| cgp 6809 |
| 84069-38-5 |
| 3-[(2r)-2-[(2r,3r,4r,5s)-5-ethoxy-4-hydroxy-3-methoxyoxolan-2-yl]-2-methoxyethyl]-1-methyl-1-nitrosourea |
| cgp-6809 |
| ethyl-6-deoxy-3,5-di-o-methyl-6-(3-methyl-3-nitrosoureido)glucofuranoside |
| SCHEMBL11226054 |
| DTXSID701004355 |
| ethyl 6-deoxy-6-({hydroxy[methyl(nitroso)amino]methylidene}amino)-3,5-di-o-methylhexofuranoside |
| PD162081 |
| AKOS040751115 |
Research Excerpts
Overview
CGP 6809 is a water-soluble nitrosourea derivative. It is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.
| Excerpt | Reference | Relevance |
|---|---|---|
| "CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer." | ( CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts. Fiebig, HH; Löhr, GW; Widmer, KH; Winterhalter, BR, 1989) | 2.44 |
| "CGP 6809 is a water-soluble nitrosourea derivative with quite distinct chemical and biological properties as compared with the well-known representatives of this class of compounds. " | ( CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties. Kanter, PM; Matter, A; Müller, M; Schieweck, K; Schmidt-Ruppin, KH; Stanek, J, 1989) | 3.16 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||